Yatai Pharma Subsidiary Plans to Invest RMB 5 Million for a 7.69% Stake in an Investment Fund

Corporate Action
โดย 财中社·CN·Read original
Summary · why it matters

Yatai Pharma's wholly-owned subsidiary, Zhejiang Yatai Lizhong Holdings, plans to invest RMB 5 million of its own funds to subscribe for expanded shares in the Qingdao Yanghe Cangqiong Venture Capital Fund Partnership, representing 7.69% of the total committed capital. The fund primarily invests in equity assets such as high-quality unlisted company shares in sectors like high-end manufacturing and non-publicly traded securities of listed companies. In the first quarter of 2026, Yatai Pharma recorded revenue of RMB 59.58 million and a net loss attributable to the parent company of RMB 2.59 million.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 2

浙江雅泰利众控股有限公司Private± Mixed
Capitalrelevance

Wholly-owned subsidiary making the investment, impact indirect and uncertain.

青岛阳和苍穹创业投资基金合伙企业Private± Mixed
Capitalrelevance

Fund receives new investment, but impact on its value is unclear.

© 2026 MarketDXNews